T1	Participants 246 261	cancer patients
T2	Participants 473 529	patients undergoing therapy with neurotoxic chemotherapy
T3	Participants 768 788	100 patients per arm
T5	Participants 1038 1057	189 evaluable cases
T6	Participants 1707 1749	patients receiving neurotoxic chemotherapy
T4	Participants 939 1026	Two-hundred seven patients were enrolled between December 1, 2006 and December 14, 2007
